Deferred registration: Quotient Sciences Code: QSC302976
| ISRCTN | ISRCTN17799325 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN17799325 |
| Integrated Research Application System (IRAS) | 1013081 |
| CRO Code | Quotient Sciences Code: QSC302976 |
| Sponsor | Epygenix Therapeutics, Inc. |
| Funder | Epygenix Therapeutics, Inc. |
- Submission date
- 29/06/2026
- Registration date
- 03/07/2026
- Last edited
- 05/08/2026
- Recruitment status
- No longer recruiting
- Overall study status
- Deferred
- Condition category
- Other
Plain English summary of protocol
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Contact information
Principal investigator
Mere Way, Ruddington Fields
Ruddington
Nottingham
NG11 6JS
United Kingdom
| Phone | +44 (0)3303031000 |
|---|---|
| recruitment@weneedyou.co.uk |
Public, Scientific
Harmony Biosciences
630 W. Germantown Pike, Suite 215
Plymouth Meeting
PA 19462
United States of America
| Phone | +1 817-773-1958 |
|---|---|
| rfaulkner@harmonybiosciences.com |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | N/A: single arm study |
| Masking | Open (masking not used) |
| Control | Uncontrolled |
| Assignment | Single |
| Purpose | Phase I trial in healthy volunteers |
| Scientific title | Deferred registration: Quotient Sciences code: QSC302976 [Full scientific title to be added on or before the deferral expiry date] |
| Study objectives | This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Ethics approval(s) |
Approved 31/07/2026, South Central - Berkshire Research Ethics Committee (Health Research Authority, 2 Reman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8178; berkshire.rec@hra.nhs.uk), ref: 26/SC/0071 |
| Health condition(s) or problem(s) studied | Healthy volunteers |
| Intervention | This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Intervention type | Drug |
| Phase | Phase I |
| Drug / device / biological / vaccine name(s) | This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) | |
| Completion date | 17/09/2026 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Mixed |
| Lower age limit | 30 Years |
| Upper age limit | 65 Years |
| Sex | Male |
| Target sample size at registration | 8 |
| Key inclusion criteria | This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Key exclusion criteria | This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Date of first enrolment | 11/08/2026 |
| Date of final enrolment | 17/09/2026 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Ruddington
Nottingham
NG11 6JS
England
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Editorial Notes
05/08/2026: The ethics approval was added.
03/07/2026: Trial's existence confirmed by MHRA.